| Valuation |
9.4 |
auto |
P/E 26.4 |
| Liquidity |
5.7 |
auto |
Current ratio 1.02 |
| Growth |
7.0 |
auto |
Revenue growth 9.9% |
| Profitability |
9.2 |
auto |
Net margin 21.8% |
| Efficiency |
9.6 |
auto |
ROE 26.4% |
| Leadership Tenure |
7.5 |
ai |
CEO Joaquin Duato took over in January 2022 from Alex Gorsky, with 35+ years at JNJ providing continuity; clean Kenvue spin-off execution but tenure still under 4 years. |
| Ownership Alignment |
3.7 |
auto |
Insider holding 0.06% |
| Strategic Vision |
7.8 |
ai |
Post-Kenvue separation focuses on Innovative Medicine + MedTech with clear pipeline strategy (Carvykti, Tremfya, Rybrevant, robotic surgery via Ottava); coherent but not category-defining vision. |
| Focus / Clarity |
7.2 |
ai |
Now a two-segment pharma + medtech pure-play after Kenvue spin, more focused than legacy JNJ but still spans oncology, immunology, neuroscience, cardiovascular, and surgical robotics. |
| Diversification |
9.2 |
ai |
~$88B revenue diversified across Innovative Medicine (~$57B) and MedTech (~$31B), no single drug >15% post-Stelara LOE, global footprint with no customer concentration. |
| Maturity / Revenue |
9.6 |
ai |
Revenue $96.4B |
| Growth Potential |
7.0 |
ai |
Stelara LOE headwind offset by Darzalex, Tremfya, Carvykti, and pipeline; oncology + medtech robotics provide upside but mid-single-digit growth profile limits ceiling vs. pure-play biotech peers. |
| Volatility |
5.5 |
auto |
β 0.33 · D/E 67.73 |
| Market Standing |
9.2 |
auto |
Market cap $548.3B |
| Competitive Moat |
7.8 |
ai |
Top-tier pharma with deep oncology/immunology IP, #1 or #2 medtech positions in surgery and orthopedics, scale R&D (~$15B annually), but faces patent cliffs and contested categories—doesn't stack to +1 boost territory. |